Placebo + Lorundrostat for hypertension

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 14 Jul 2023: Trial started, NCT05968430
  2. 1 Aug 2023: Trial registered, NCT05968430

The trials

NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

State
Under way
Phase
Phase 3
People
1,076 taking part
Started
14 Jul 2023
Primary completion
30 Dec 2025
Arms
RTW Substudy
Results
None posted
  1. 14 Jul 2023: Trial started
  2. 1 Aug 2023: Trial registered

NCT06785454: A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

State
Completed
Phase
Phase 2
People
48 taking part
Started
28 Feb 2025
Primary completion
17 Dec 2025
Arms
Sequence 1: Lorundrostat then Placebo, Sequence 2: Placebo then Lorundrostat
Results
None posted
  1. 21 Jan 2025: Trial registered
  2. 28 Feb 2025: Trial started
  3. 29 Dec 2025: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.